Postdoctoral Position in Cancer Immunotherapy: The University of Liège (Belgium) invites applications for a postdoctoral researcher to join a high-impact, collaborative research project at the FARAH and GIGA Institutes. The focus is on exploring how viral imprinting of myeloid cells influences response to PD-L1 blockade in cancer immunotherapy. The selected candidate will work with top-tier immunologists and oncologists in a stimulating, international research environment equipped with cutting-edge facilities.
Postdoctoral Position – Viral Imprinting of Myeloid Cells in Cancer Immunotherapy
📋 Summary Table
| Field | Details |
|---|---|
| Designation | Postdoctoral Researcher |
| Research Area | Cancer Immunotherapy, Viral Immunology, Myeloid Cell Biology |
| Location | FARAH and GIGA Institutes, University of Liège, Belgium |
| Start Date | Flexible (preferably between October 2025 and January 2026) |
| Contract | 1-year initial contract, renewable up to 2 additional years |
| Eligibility | Ph.D. with relevant expertise; mobility rule applies |
| Application Deadline | Not specified – Apply as soon as possible |
🧑🔬 Designation
Postdoctoral Researcher
🔬 Research Area
- Viral Imprinting
- Myeloid Cell Function
- Cancer Immunotherapy (α-PD-L1 therapy)
- In vivo Disease Models
- Multi-omic & Spatial Transcriptomics
📍 Location
FARAH and GIGA Institutes,
University of Liège, Belgium
✅ Eligibility / Qualification
- Ph.D. in Biomedical Sciences, Biology, Biochemistry, Pharmaceutical Sciences, Veterinary Medicine, or related field
- Strong expertise in:
- Cellular Immunology and in vivo models
- Animal handling and procedures
- Multi-parameter flow cytometry
- Desirable: Experience with cancer immunotherapy and transcriptomic analyses
- Proven scientific writing and communication skills in English
- Mobility Rule: Must not have resided or worked in Belgium for more than 12 months in the past 3 years
📝 Job Description
The candidate will contribute to a collaborative project investigating the influence of viral imprinting on the behavior of myeloid cells in response to PD-L1 blockade using Murid herpesvirus-4 (MuHV4) in murine models. Tasks include:
- Designing and performing mechanistic and multi-omic studies
- Analyzing systemic and tumor microenvironmental changes
- Contributing to high-impact publications
- Working closely with a multi-disciplinary team of virologists, immunologists, and oncologists
🎁 What We Offer
- 1-year contract with possible 2-year extension
- Access to state-of-the-art facilities:
- BSL2/3 animal labs
- In vivo/in vitro imaging
- Spectral cytometers, 10X Genomics, Rhapsody single-cell tools
- Close mentorship by experienced researchers:
- Dr. Bénédicte Machiels (Viro-immunology, ERC Starting Grant)
- Prof. Thomas Marichal (Immunophysiology, ERC Consolidator Grant)
- Dr. Michael Herfs (Experimental Oncology)
- Opportunity to participate in international conferences and specialized training
📧 How to Apply
Send a single PDF containing:
- CV
- Motivation letter (highlighting research experience and fit for this project)
- Contact details of two referees
Email to:
📅 Last Date to Apply
Not specified — applications are reviewed on a rolling basis. Early submission is strongly encouraged.
For reference publications, please consult recent works by the PIs in Science Immunology, Nature Immunology, J Immunother Cancer, PNAS, and Nature Communications (2017–2025).
